First-line chemotherapy regimens for locally advanced and metastatic pancreatic adenocarcinoma: a Bayesian analysis

References

• ColucciGGiulianiFGebbiaVGemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia MeridionaleCancer200294490291011920457
   PubMed Web of Science ®Google Scholar
• BramhallSRSchulzJNemunaitisJBrownPDBailletMBuckelsJAA double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBritish journal of cancer200287216116712107836
   PubMed Web of Science ®Google Scholar
• MaiseyNChauICunninghamDMulticenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology200220143130313612118027
   PubMed Web of Science ®Google Scholar
• BerlinJDCatalanoPThomasJPKuglerJWHallerDGBensonAB3rdPhase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297Journal of clinical oncology : official journal of the American Society of Clinical Oncology200220153270327512149301
   PubMed Web of Science ®Google Scholar
• DucreuxMRougierPPignonJPA randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinomaAnnals of oncology : official journal of the European Society for Medical Oncology20021381185119112181240
   PubMed Web of Science ®Google Scholar
• SmithDGallagherNA phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancerEuropean journal of cancer (Oxford England 1990)2003391013771383
   PubMed Web of Science ®Google Scholar
• MooreMJHammJDanceyJComparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJournal of clinical oncology : official journal of the American Society of Clinical Oncology200321173296330212947065
   PubMed Web of Science ®Google Scholar
• DucreuxMMitryEOuld-KaciMRandomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patientsAnnals of oncology : official journal of the European Society for Medical Oncology200415346747314998850
   PubMed Web of Science ®Google Scholar
• CutsemEVeldeHKarasekPPhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology200422814301438 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/333/CN-00468333/frame.html15084616
   PubMed Web of Science ®Google Scholar
• Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJournal of clinical oncology : official journal of the American Society of Clinical Oncology200422183776378315365074
   PubMed Web of Science ®Google Scholar
• CantoreMFiorentiniGLuppiGGemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in OncologyJournal of chemotherapy (Florence, Italy)2004166589594
   PubMed Web of Science ®Google Scholar
• ChenJRockenCNitscheBThe tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progressionCancer letters2006233232833715893416
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJournal of clinical oncology : official journal of the American Society of Clinical Oncology200523153509351615908661
   PubMed Web of Science ®Google Scholar
• Di CostanzoFCarliniPDoniLGemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC)British journal of cancer200593218518915986036
   PubMed Web of Science ®Google Scholar
• ChauICunninghamDRussellCGastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trialsBritish journal of cancer20069481107111516622436
   PubMed Web of Science ®Google Scholar
• RichardsDBoehmKWaterhouseDGemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter studyAnnals of oncology : official journal of the European Society for Medical Oncology200617710961102 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/464/CN-00570464/frame.html16641168
   PubMed Web of Science ®Google Scholar
• StathopoulosGPSyrigosKAravantinosGA multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish journal of cancer200695558759216909140
   PubMed Web of Science ®Google Scholar
• HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology200624243946395216921047
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology2006242744414447 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/068/CN-00568068/frame.html16983112
   PubMed Web of Science ®Google Scholar
• FriessHLangrehrJOettleHA randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancerBMC cancer20066285 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/309/CN-00574309/frame.html17156477
   PubMed Web of Science ®Google Scholar
• BoeckSHoehlerTSeipeltGCapecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancerAnnals of oncology : official journal of the European Society for Medical Oncology200819234034717962204
   PubMed Web of Science ®Google Scholar
• CascinuSBerardiRLabiancaRCetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialThe Lancet Oncology200891394418077217
   PubMed Web of Science ®Google Scholar
• WiedenmannBMalfertheinerPFriessHA multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaThe journal of supportive oncology200861182518257397
   PubMedGoogle Scholar
• SpanoJPChodkiewiczCMaurelJEfficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II studyLancet (London, England)2008371963021012108
   PubMed Web of Science ®Google Scholar
• EckhardtSPorrePSmithDPatient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancerJournal of pain and symptom management2009372135143 http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/229/CN-00682229/frame.html18723314
   PubMed Web of Science ®Google Scholar
• PoplinEFengYBerlinJPhase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupJournal of clinical oncology : official journal of the American Society of Clinical Oncology200927233778378519581537
   PubMed Web of Science ®Google Scholar
• SaifMWOettleHVervenneWLRandomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreasCancer journal (Sudbury, Mass)2009154339343
   PubMed Web of Science ®Google Scholar
• RichardsDAKueflerPRBecerraCGemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative studyInvestigational new drugs201129114415319714296
   PubMed Web of Science ®Google Scholar
• CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology200927335513551819858379
   PubMed Web of Science ®Google Scholar
• MeyerTCaplinMEPalmerDHA phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancerEuropean journal of cancer (Oxford England 1990)2010463526533
   PubMed Web of Science ®Google Scholar
• ColucciGLabiancaRDi CostanzoFRandomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 studyJournal of Clinical Oncology201028101645165120194854
   PubMed Web of Science ®Google Scholar
• KindlerHLNiedzwieckiDHollisDGemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303)Journal of clinical oncology : official journal of the American Society of Clinical Oncology201028223617362220606091
   PubMed Web of Science ®Google Scholar
• PhilipPABenedettiJCorlessCLPhase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Journal of clinical oncology : official journal of the American Society of Clinical Oncology201028223605361020606093
   PubMed Web of Science ®Google Scholar
• KindlerHLIokaTRichelDJAxitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 studyThe Lancet Oncology201112325626221306953
   PubMed Web of Science ®Google Scholar
• ReniMCeredaSRognoneAA randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)Cancer chemotherapy and pharmacology201269111512321626049
   PubMed Web of Science ®Google Scholar
• HeinrichJCTuukkanenASchroederMFahrigTFahrigRRP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patientsJournal of cancer research and clinical oncology201113791349136121833720
   PubMed Web of Science ®Google Scholar
• LohrJMHaasSLBechsteinWOCationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trialAnnals of oncology : official journal of the European Society for Medical Oncology20122351214122221896540
   PubMed Web of Science ®Google Scholar
• MaraveyasAWatersJRoyRGemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancerEuropean journal of cancer (Oxford England 1990)201248912831292
   PubMed Web of Science ®Google Scholar
• GilliamADBroomePTopuzovEGAn international multicenter randomized controlled trial of G17DT in patients with pancreatic cancerPancreas201241337437922228104
   PubMed Web of Science ®Google Scholar
• OzakaMMatsumuraYIshiiHRandomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)Cancer chemotherapy and pharmacology20126951197120422249272
   PubMed Web of Science ®Google Scholar
• GoncalvesAGilabertMFrancoisEBAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancerAnnals of oncology : official journal of the European Society for Medical Oncology201223112799280522771827
   PubMed Web of Science ®Google Scholar
• MengZGarrettCRShenYProspective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomasBritish journal of cancer2012107341141622782343
   PubMed Web of Science ®Google Scholar
• HongJYNamEMLeeJRandomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patientsCancer chemotherapy and pharmacology201473112513024162380
   PubMed Web of Science ®Google Scholar
• CascinuSBerardiRSobreroASorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II studyDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2014462182186
   PubMedGoogle Scholar
• BergmannLMauteLHeilGA prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIVEuropean journal of cancer (Oxford England 1990)20155112736
   PubMed Web of Science ®Google Scholar
• BoradMJReddySGBaharyNRandomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of clinical oncology : official journal of the American Society of Clinical Oncology201533131475148125512461
   PubMed Web of Science ®Google Scholar
• BendellJO’ReillyEMMiddletonMRPhase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancerAnnals of oncology : official journal of the European Society for Medical Oncology201526480481125573533
   PubMed Web of Science ®Google Scholar
• DeplanqueGDemarchiMHebbarMA randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancerAnnals of oncology : official journal of the European Society for Medical Oncology20152661194120025858497
   PubMed Web of Science ®Google Scholar
• YamaueHTsunodaTTaniMRandomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC StudyCancer science2015106788389025867139
   PubMed Web of Science ®Google Scholar
• KordesSPollakMNZwindermanAHMetformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology201516783984726067687
   PubMed Web of Science ®Google Scholar
• DalgleishAGStebbingJJa AdamsonDRandomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerBritish journal of cancer2016115778979627599039
   PubMed Web of Science ®Google Scholar
• LaquenteBLopez-MartinJRichardsDA phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patientsBMC Cancer201717113728202004
   PubMed Web of Science ®Google Scholar
• MiddletonGPalmerDHGreenhalfWVandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trialThe Lancet Oncology201718448649928259610
   PubMed Web of Science ®Google Scholar